Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?
Authors:
- 1 August 2018
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 33 (8) , 1228-1235
Abstract
Among movement disorders and medicine in general, PD is one of the conditions for which there is a greater knowledge of the placebo and nocebo responses. In other movement disorders, the knowledge of placebo and nocebo responses is less. An advance in this field is expected to contribute to a better understanding of the nature of a therapeutic benefit in clinical research and clinical practice, and mechanisms of placebo and nocebo. We conducted a review on placebo and nocebo responses in other movement disorders besides PD by primarily examining meta‐analyses of clinical trials assessing specifically the placebo and/or nocebo responses. Second, we examined both efficacy and safety results of a placebo arm in pivotal placebo‐controlled trials for the different movement disorders. RLS is the movement disorder for which the most data exist, followed by tic disorders and Huntington's disease. Data available in other conditions document a placebo response in a varied phenomenology. We found different placebo responses according to clinical domains assessed, type of outcomes used for the same clinical domain, and modes of treatment administration, including rehabilitation and surgical interventions. Data on the nocebo response were very scarce. Although the data available are limited, RLS has the better documentation of placebo and nocebo responses. In contrast, atypical parkinsonisms are the group of movement disorders with the least knowledge. The clinical entities with a more robust placebo response are those that have the most beneficial available symptomatic treatments. © 2018 International Parkinson and Movement Disorder SocietyKeywords
This publication has 59 references indexed in Scilit:
- Impact of placebo assignment in clinical trials of tic disordersMovement Disorders, 2013
- Donepezil for dementia with Lewy bodies: A randomized, placebo‐controlled trialAnnals of Neurology, 2012
- A randomized trial of mesenchymal stem cells in multiple system atrophyAnnals of Neurology, 2012
- Placebo effect characteristics observed in a single, international, longitudinal study in Huntington's diseaseMovement Disorders, 2011
- European clinical guidelines for Tourette Syndrome and other tic disorders. Part I: assessmentEuropean Child & Adolescent Psychiatry, 2011
- Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studiesBrain, 2007
- Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulationMovement Disorders, 2006
- The European Multiple System Atrophy-Study Group (EMSA-SG)Journal of Neural Transmission, 2005
- Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's DiseaseScience, 2001
- What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using DysportJournal of Neurology, Neurosurgery & Psychiatry, 1998